Get the Stockscreener App
0.00
100.00%
-4.66
Curevac N V stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
See More
Previous Close:
$4.66
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$1.05B
Revenue:
$596.48M
Net Income/Loss:
$123.72M
P/E Ratio:
0.00
EPS:
0.5484
Net Cash Flow:
$106.59M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$5.72
Curevac N V Stock (CVAC) Company Profile
Compare CVAC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVAC
Curevac N V
|
0.00 | 1.05B | 596.48M | 123.72M | 106.59M | 0.5484 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.90 | 120.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.45 | 78.77B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
840.50 | 52.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
338.06 | 45.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
340.38 | 38.73B | 4.98B | 69.59M | 525.67M | 0.5197 |
Curevac N V Stock (CVAC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-13-25 | Downgrade | Jefferies | Buy → Hold |
| Apr-25-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-08-23 | Initiated | SVB Securities | Outperform |
| Jan-19-23 | Upgrade | UBS | Neutral → Buy |
| Jan-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jan-21-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-18-22 | Initiated | JMP Securities | Mkt Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Hold |
| Jun-17-21 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-26-21 | Resumed | Credit Suisse | Underperform |
| Apr-26-21 | Initiated | Guggenheim | Neutral |
| Dec-10-20 | Downgrade | Credit Suisse | Neutral → Underperform |
| Sep-08-20 | Initiated | BofA Securities | Buy |
| Sep-08-20 | Initiated | Credit Suisse | Neutral |
| Sep-08-20 | Initiated | Jefferies | Hold |
View All
Curevac N V Stock (CVAC) Latest News
CureVac Shares Cease Trading Following BioNTech Acquisition - AD HOC NEWS
CureVac Aktie: Strategische Prioritäten - Börse Global
Block Trades: How does SIFY score in quality rankingsInflation Watch & Safe Capital Growth Stock Tips - baoquankhu1.vn
Aug Wrap: Should you avoid CureVac NV stock right nowJuly 2025 Update & Safe Capital Growth Stock Tips - baoquankhu1.vn
Can CureVac N.V. outperform under higher oil pricesJuly 2025 Macro Moves & Scalable Portfolio Growth Methods - mfd.ru
Toyota and Georg Fischer HR veteran to lead BioNTech's global people strategy - Stock Titan
BioNTech Consolidates mRNA Sector with CureVac Acquisition Finalized - AD HOC NEWS
CureVac Concludes Acquisition by BioNTech, Exits Public Markets - AD HOC NEWS
CureVac Shareholders Face Final Tax Reclaim Deadline () - aktiencheck.de
CureVac's Public Market Journey Concludes Following BioNTech Acquisition () - aktiencheck.de
CureVac Exits Public Markets Following BioNTech Acquisition - AD HOC NEWS
BioNTech Completes CureVac Acquisition and Delisting - AD HOC NEWS
CureVac N.V. (CVAC) Investor Outlook: Navigating the Biotechnology Terrain Amidst Strategic Acquisitions - DirectorsTalk Interviews
Earnings Recap: How does XNET score in quality rankingsEarnings Recap Summary & AI Enhanced Trading Signals - baoquankhu1.vn
CureVac (NasdaqGM:CVAC) Valuation After New mRNA Pipeline Progress And Refined Capital Allocation Plan - Yahoo Finance
CureVac Shares Cease Trading Following BioNTech Acquisition Finalization - AD HOC NEWS
CureVac Shares Cease Trading as BioNTech Acquisition Finalizes - AD HOC NEWS
BioNTech’s CureVac Deal Put A Floor Under A Volatile Stock - Finimize
How CureVac N.V. stock reacts to Fed rate cuts2025 Performance Recap & Consistent Growth Equity Picks - Bộ Nội Vụ
Seven big cancer studies BioNTech will report on in 2026 - Stock Titan
CureVac N.V. (NASDAQ:CVAC) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
CureVac’s Market Exit: A New Chapter Begins Under BioNTech - AD HOC NEWS
CureVac’s Stock Market Exit Finalized Following BioNTech Acquisition - AD HOC NEWS
BioNTech Finalizes CureVac Acquisition: A Strategic Consolidation Met with Market Skepticism - The Chronicle-Journal
How CureVac N.V. stock responds to policy changesEarnings Overview Report & Daily Stock Trend Watchlist - Улправда
Does CureVac’s (CVAC) NASDAQ Exit Quietly Recast Its Risk Profile and Equity Story? - simplywall.st
Update Recap: Why CureVac N.V. stock remains on buy listsDip Buying & AI Enhanced Market Trend Forecasts - Улправда
Why CureVac N.V. stock remains on buy listsTrade Risk Report & Long-Term Investment Growth Plans - Улправда
Weekly Trades: What sentiment indicators say about CureVac N.V. stockQuarterly Portfolio Review & Daily Volume Surge Signals - Улправда
How CureVac N.V. stock performs after earningsJuly 2025 Selloffs & Real-Time Stock Price Movement Reports - Улправда
CureVac’s Final Trading Day: A Chapter Closes in the mRNA Sector - AD HOC NEWS
CureVac completes BioNTech-driven reorganization and moves to delist from Nasdaq - MSN
CureVac Shareholders Face Final Chapter as BioNTech Merger Closes () - aktiencheck.de
BioNTech completes CureVac takeover and updates articles of association - MSN
CureVac shares to be delisted from Nasdaq following BioNTech acquisition By Investing.com - Investing.com Nigeria
CureVac’s Stock Market Exit Marks End of an Era for mRNA Pioneer - AD HOC NEWS
CureVac Completes BioNTech-Driven Reorganization and Moves to Delist from Nasdaq - TipRanks
BioNTech Completes CureVac Takeover and Updates Articles of Association - TipRanks
CureVac shares to be delisted from Nasdaq following BioNTech acquisition - Investing.com
CureVac Shareholders Approve BioNTech Exchange Offer - MSN
CureVac's Public Market Journey Concludes with BioNTech Merger Finalization () - aktiencheck.de
CureVac NV’s CVAC Stock: Volatile Gene?Therapy Bet Faces Tough Crowd On Wall Street - AD HOC NEWS
BioNTech’s Strategic Pivot Validated by Recent Developments - AD HOC NEWS
CureVac (NASDAQ:CVAC) Reaches New 12-Month HighWhat's Next? - MarketBeat
BioNTech Consolidates mRNA Leadership with CureVac Acquisition Finalization - AD HOC NEWS
Fundamentals Check: so 6 y nghia la giInsider Buying & Low Risk High Win Rate Stock Picks - moha.gov.vn
A New Chapter Begins: BioNTech Completes CureVac Acquisition - AD HOC NEWS
BioNTech Consolidates mRNA Leadership with CureVac Acquisition Finalized - AD HOC NEWS
BioNTech SE (BNTX) Closes the Acquisition of CureVac N.V. - Finviz
CureVac’s Final Chapter: BioNTech Acquisition Paves Way for Delisting - AD HOC NEWS
Curevac N V Stock (CVAC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):